DNMT3A and Miyoshi myopathy: DNMT3A/B are targeted by miRNAs, such as miR-29b, whose restoration efficiently reduces global DNA methylation leading to a strong anti-MM effect in vitro and in vivo in the SCID-synth-hu model [116], either as a single agent or in combination with demethylating agents [116], HDAC inhibitors [122] or proteasome inhibitors [123].